Nonetheless, more clinical trials are ongoing to evaluate tezepelumab efficacies in other TSLP-mediated allergic, inflammatory, and autoimmune disorders that include severe chronic rhinosinusitis with nasal polyposis, chronic obstructive pulmonary disease, and chronic spontaneous urticaria. This evidence concerns the gene TSLP and Nasal polyposis.